2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
GlobalData on MSN5d
FDA approves BridgeBio’s Attruby for ATTR-CM treatmentThe US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
2don MSNOpinion
See the new treatment that will break a Pfizer monopoly on a drug for heart disease.
TipRanks on MSN7d
BridgeBio announces FDA approved Attruby for ATTR-CM patientsPharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...
Zacks.com on MSN4d
BridgeBio Stock Up on FDA Approval of Cardiovascular DrugBridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback